$21M Compounding Pharmacy Exposes Why Peptides are Trending | Ep. 407 with Kris Fishman CEO and President of Wells Pharmacy Network

Daniel and Kris Fishman explore why compounding pharmacies are suddenly part of the national health conversation, especially as GLP-1s, peptides, and personalized medicine become mainstream. Kris breaks down what compounding actually means, why “one size fits all” medicine is being questioned, and how pharmacies like Wells step in when traditional options are unavailable or not personalized enough. The conversation also covers FDA scrutiny, peptide regulation, Big Pharma tension, operational scale, and the emotional reality of leading a fast-growing healthcare company.

Key Discussion Points

Kris explains that compounding pharmacies go back centuries and combine active pharmaceutical ingredients to create personalized preparations when standard retail versions do not fit a patient’s needs. 
He breaks down why peptides became a major health trend, describing them as amino acid chains that have gained traction through wellness culture, social media, and gray-market demand. 
Kris discusses the FDA’s review process and the importance of the upcoming PCAC meeting, where physicians and pharmacists can explain why certain peptides should be available for compounding. 
He explains that Wells Pharmacy Network focuses on quality, testing, sterile processes, and transparency, encouraging people to research their pharmacy and understand its safety standards. 
Kris shares that the company’s operational unlock came from improving speed, technology, and order fulfillment while maintaining strict quality control. 
He talks about the tension with Big Pharma, especially after GLP-1 shortages, and argues compounding exists to help patients where personalized or unavailable options are needed. 
Kris says the biggest CEO pressure is not product quality, because he trusts his team, but making sure regulators understand the data, adverse effects, and patient impact behind the products they carry. 
He opens up about the personal cost of leadership, including missing much of his children’s lives while building the company, and the tradeoff of trying to provide a better future for them.

Takeaways

Personalized medicine is growing because more people are questioning whether one-size-fits-all healthcare actually serves their needs. 
The biggest misunderstanding about compounding is safety, which is why quality controls, testing, and regulatory transparency matter. 
Peptides are popular, but Kris warns that people should avoid gray-market options and work through qualified doctors and reputable pharmacies. 
Scaling in healthcare requires both speed and trust, because getting products out quickly means nothing if quality is compromised. 
Leadership can create real personal sacrifice, and Kris reflects honestly on the cost of building while raising a family.

Closing Thoughts

Kris Fishman’s story shows the intersection of healthcare, entrepreneurship, regulation, and personal mission. What started as an industry he did not fully understand became a calling after seeing patients and family members benefit from personalized products. This episode gives listeners a clearer picture of why compounding pharmacies matter, why peptides are everywhere, and why the future of medicine may depend on safer, smarter personalization.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.